Last reviewed · How we verify
JVS-100
At a glance
| Generic name | JVS-100 |
|---|---|
| Sponsor | Juventas Therapeutics, Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- SDF1 Plasmid Treatment for Patients With Peripheral Artery Disease (PHASE2)
- Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Critical Limb Ischemia (PHASE2)
- Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure (PHASE1, PHASE2)
- Registry to Assess Safety for Subjects That Have Completed a Juventas Sponsored HF Protocol Under IND # 14203
- Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure. (PHASE2)
- Study to Evaluate the Safety and Efficacy of Dermal Injections of JVS-100 Given to Adults Receiving Median Sternotomy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JVS-100 CI brief — competitive landscape report
- JVS-100 updates RSS · CI watch RSS
- Juventas Therapeutics, Inc. portfolio CI